Cannacord Genuity lifts easyJet to a 'hold' after management raises guidance

Alexander Bueso WebFG News | 12 Oct, 2017 15:38 | | |

ep flota deasyjet
Flota d'easyJetEASYJET



17:20 15/12/17
  • 7,490.57
  • 0.57%42.45
  • Max: 7,490.57
  • Min: 7,433.78
  • Volume: 0
  • MM 200 : n/a
17:25 15/12/17
  • 9,870.58
  • 0.52%50.62
  • Max: 9,870.58
  • Min: 9,808.78
  • Volume: 0
  • MM 200 : n/a
17:25 15/12/17
  • 4,162.18
  • 0.51%21.06
  • Max: 4,162.18
  • Min: 4,133.41
  • Volume: 0
  • MM 200 : n/a
17:25 15/12/17
  • 4,108.96
  • 0.50%20.38
  • Max: 4,108.96
  • Min: 4,081.00
  • Volume: 0
  • MM 200 : n/a
17:25 15/12/17

Analysts at Cannacord Genuity raised their recommendation on shares of easyJet from 'sell' to 'hold', arguing that better-than-expected Summer 2017 trading would provide greater-than-expected lift for the shares.

The budget carrier's revenues per share fell by 1.4% over the summer, but that was better than the 2% drag they had penciled in, which meant profits before tax were now likely to come in towards £405m to $410m, as per management's revised guidance, versus a previous view for between £380m to £420m.

Greater competition was still expected to prove a headwind for the firm's profit recovery versus the lofty levels reached a couple of years ago, although easyJet's own capacity growth deceleration in 2017/18 would act as a partial offset, they said.

All told, Cannacord raised its target price for the stock from 1,150p to 1,200p, yet with less than 10% downside potential remaining it upgraded its view on the shares.

The Canadian broker also upped its forecasts for earnings per share for 2016/17 by 6.2% to 84.0p, on the back of which it also nudged up its estimate for the company's dividend per share from 36.7p to 38.9p.

More news

15 Dec London close: Footsie gains as pound drops, Wall Street hits fresh highs

The top flight index recovered some ground on Friday, but mostly on account of weakness in Sterling after German Chancellor Angela Merkel reportedly echoed other European Union officials, saying "the most difficult phase is ahead of us".

15 Dec Week ahead: US data, Catalan elections in focus

The focus in the coming week will continue to be on the ebb and flow of data out of the US, including Republicans' progress on securing passage of their tax cuts.

15 Dec US open: Stocks jump as Republicans move to secure passage of tax cuts

Wall Street is heading higher again on Friday amid news that Republicans were tweaking their proposed tax cuts in order to secure prompt passage of the US tax bill.

15 Dec Airbus chief executive to step down in board shake-up

The chief executive of French planemaker Airbus will step down from his position in 2019 as the company announced a major shake-up of its management team.

15 Dec FTSE 250 movers: TalkTalk rises but Serco gives back gains

London’s FTSE 250 was up 0.1% to 20,023.23 in afternoon trade on Friday as the Christmas lull kicked in.

15 Dec US industrial production rises slightly less than expected in November

Industrial production in the States rose slightly less quickly than expected last month, despite higher output of business equipment and materials.

15 Dec Strategic Minerals renegotiates acquisition of Leigh Creek Copper Mine

Diversified mineral production and development company Strategic Minerals announced on Friday that, after the successful completion of technical and financial due diligence on the Leigh Creek Copper Mine company, it has agreed to continue with the acquisition on renegotiated terms.

15 Dec FTSE 100 movers: Sky jumps but retailers retreat on H&M sales

London’s FTSE 100 was up 0.3% to 7,469.23 in quiet afternoon trade on Friday.

15 Dec Gfinity partners with Microsoft for next Halo World Championship

International esports entertainment group Gfinity has been named as a preferred event partner to Microsoft for the forthcoming ‘Halo World Championship 2018’ for the next season, it announced on Friday.

15 Dec Hutchison Chi-Med begins fruquintinib trial in US

Hutchison China MediTech, known as Chi-Med, has initiated the United States Phase I bridging clinical trial of fruquintinib, it announced on Friday.